Our Team

Our  team is committed to our purpose to transform the treatment of opioid use disorder.

Natalie Budilovsky, Medical Affairs

Natalie R. Budilovsky-Kelley

Medical Affairs

Josh Cohen, Chief Medical Officer

Joshua Cohen

Chief Medical Officer

Judy Cohen, Manufacturing Operations

Judith H. Cohen

Manufacturing Operations

Tom Connolly, Sales

Tom Connolly


Mike Derkacz, CEO

Mike Derkacz

President & CEO

Brian Hirsch, General Counsel

Brian Hirsch

General Counsel

Paul Johnson, Chief Commercial Officer

Paul Johnson

Chief Commercial Officer

Ruchira Kannambille, Regulatory

Ruchira Kannambille

Regulatory Affairs

Rob Laverty, Market Access

Rob Laverty

Market Access

Renata Rauth, HR

Renata Rauth

Human Resources

Louis Ricigliano, Chief Financial Officer

Louis Ricigliano

Chief Financial Officer

Colleen Saltmer, Communications

Colleen Saltmer


Board of Directors

Seth Harrison, MD

Chairman of the Board & Inside Director

Dr. Seth Harrison is the managing partner of Apple Tree Partners and serves as Executive Chairman of Braeburn Pharmaceuticals. He has invested in life sciences since 1991. Seth has served as founding investor, acting CEO or chairman of numerous portfolio companies. Previously, Seth was a general partner at Oak Investment Partners and earlier was a venture partner at Sevin Rosen Funds. From 2002 – 2010 he served on the board of the International Partnership for Microbicides, a Rockefeller Foundation/Gates Foundation sponsored public-private partnership engaged in the development of anti-HIV microbicides.

Mike Derkacz

President, CEO & Inside Director

Mike Derkacz leads Braeburn with passion and clarity, bringing 25 years of pharmaceutical industry experience to his role. Mike is an accomplished and highly successful leader, with deep expertise in building market-leading brands, conducting award-winning product launches, creating highly effective teams and developing sound commercial strategies to sustain market leadership. Prior to Braeburn, he was Senior Vice President and Head of Global CNS for Teva’s Global Specialty Medicines business. During his tenure at Teva, he led the launch of Copaxone 40mg, considered one of the most successful product introductions in the multiple sclerosis category and named pharma industry “Brand of the Year”. He joined Teva through the acquisition of Cephalon, where he served as Vice President, CNS Business unit. He spent the first 15 years of his career at GlaxoSmithKline — where he assumed positions of increasing leadership and commercial responsibility for major CNS and Cardiovascular brands.

Dennis H. Langer, M.D., J.D.

Independent Director

Dr. Dennis H. Langer has served as a Director of several biotechnology, specialty pharmaceutical, and diagnostic companies, and has been CEO and/or co-founder of several healthcare companies. Previously, Dennis served as a Managing Partner of Phoenix IP Ventures, a private equity/venture capital firm specializing in life sciences. Prior to that, he was President, North America, of Dr. Reddy’s Laboratories. Dennis has also held several leadership positions at GlaxoSmithKline and its predecessor, SmithKline Beecham, including Senior Vice President of Research and Development. He was President and CEO of Neose Technologies, Inc., and also held R&D and marketing positions at Eli Lilly, Abbott and Searle. He began his career as a Chief Resident at Yale University School of Medicine, and held clinical fellowships at Harvard Medical School and the National Institutes of Health. He serves as a Director of Myriad Genetics, Inc., Dicerna Pharmaceuticals, Inc., Delcath Systems, Inc., and several private companies. He is a Clinical Professor in the Department of Psychiatry, Georgetown University School of Medicine.

Patrick J. Kennedy

Independent Director

Patrick J. Kennedy is a former member of the U.S. House of Representatives and the nation’s leading political voice on mental illness, addiction, and other brain diseases. During his 16-year career representing Rhode Island in Congress, he fought a national battle to end medical and societal discrimination against these illnesses, highlighted by his lead sponsorship of the Mental Health Parity and Addiction Equity Act of 2008. Patrick has since founded The Kennedy Forum, which leads a national dialogue on transforming mental health and addiction care delivery by uniting mental health advocates, business leaders, and government agencies, and co-founded One Mind, a global leader in open science collaboration in brain research. He is also the co-author of “A Common Struggle: A Personal Journey Through the Past and Future of Mental Illness and Addiction,” which details his personal struggles as well as his bold plan for the future of mental health care in America.

Anna Batarina


Anna Batarina, a partner at ATP, is a leader in international business, capital markets, corporate finance, and strategy. Anna joined ATP in 2016 from Braeburn, an ATP portfolio company, where she served as vice president of Strategic Development. Before Braeburn, she was a member of the strategy team at the Global Fund to Fight AIDS, Tuberculosis and Malaria. Prior to that, Anna was senior vice president and head of Capital Markets and Investor Relations at Uralkali, a leading global agrochemical business, where she led one of the most successful IPOs on the London Stock Exchange.

Jerry Karabelas, Ph.D.


Dr. Jerry Karabelas has held a number of senior executive positions in major pharmaceutical companies, including Head of Healthcare and CEO of Worldwide Pharmaceuticals for Novartis AG, where he had full responsibility for Novartis Pharma and Ciba Vision, as well as strategic and operational leadership of R&D. He was also Executive Vice President of SmithKline Beecham with responsibility for U.S. and European operations, regulatory, and strategic marketing. Most recently, Jerry has chaired the boards of several biopharmaceutical companies, including Human Genome Sciences, Inc., Vanda Pharmaceuticals, Inc. and SkyePharma PLC. He currently chairs the boards of Inotek and Polyphor, AG and is a partner at Care Capital.

Joseph Yanchik


Joseph Yanchik, a venture partner at ATP, has been founding and funding life science companies for more than 20 years. In 2005, Joe founded ATP portfolio company Tokai Pharmaceuticals, focused on biopharmaceutical treatments for prostate cancer, serving as president and CEO from 2005 to 2008 and then as a director through 2017. Concurrently, Joe founded ATP portfolio company Aileron Therapeutics, focused on developing a novel class of stabilized cell-permeating peptides called stapled peptides, for cancer and other diseases. He established a $1.1 billion partnership between Aileron Therapeutics and Roche Pharmaceuticals and led Aileron from inception to public listing, serving as president, CEO, and director from 2006 to 2018.

More from Braeburn’s Leaders

Braeburn is committed to working with stakeholders and advocacy groups to improve outcomes for patients and their families. Check out our CEO’s testimony at the 43 minute mark.

Define the future at Braeburn...together.

Join Our Team